Alligator Bioscience (ATORX) Q4 2024 earnings summary

Executive summary

• Achieved all 2024 milestones, including top-line OPTIMIZE-1 data, interim phase I data for 527, and positive mitazalimab clinical results with 14.9 months median OS and 36.2% 18-month OS rate in metastatic pancreatic cancer.

• Focus sharpened on mitazalimab, with a cost-reduction program expected to save at least SEK 65 million annually and significant organizational restructuring.

• Announced and completed a SEK 280 million rights issue, secured bridge loans, and engaged in multiple partnering discussions to support mitazalimab advancement.

• Sale of future financial commitments for two bispecific antibodies to Orion Corporation provided non-dilutive income.

• Additional promising data for bispecific antibody ALG.APV-527 and first patient dosed in HLX22/AC101 Phase 3 trial.

Financial highlights

• Net sales for Q4 2024 were SEK 41.8 million, primarily from the termination of a collaboration agreement with Orion; full-year net sales were SEK 57.8 million.

• Operating loss for Q4 2024 was SEK -60.1 million; full-year operating loss was SEK -229.1 million.

• Cash and cash equivalents at year-end 2024 were SEK 64.3 million, including bridge financing tied to the rights issue.

• SEK 40.4 million write-down related to unused lab facility due to restructuring.

• Earnings per share for 2024 was SEK -0.32.

Outlook and guidance

• 24-month follow-up data from OPTIMIZE-1 and top-line data from the 450 microgram cohort expected in Q1 2025.

• Additional mitazalimab data to be published in H1 2025; phase III initiation targeted for H2 2025 with a partner.

• Rights issue proceeds and cost savings expected to support value inflection points and potential licensing deals in 2025.